Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity

References

• EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. European association for the Study of the Liver (EASL) & European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). Diabetologia. 2016;59:1121–1140.
   PubMedGoogle Scholar
• Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–1914.e1.
   PubMed Web of Science ®Google Scholar
• Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–1153.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898–1906.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic steato-hepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321.
   PubMed Web of Science ®Google Scholar
• Papagianni M, Sofogianni A, Tziomalos K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol. 2015;7(4):638–648.
   PubMed Web of Science ®Google Scholar
• Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1209–1222.
   PubMed Web of Science ®Google Scholar
• Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58(5):1007–1019.
   PubMed Web of Science ®Google Scholar
• Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):33.
   PubMed Web of Science ®Google Scholar
• Silaghi CA, Silaghi H, Colosi HA, et al. Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population. Clujul Med. 2016;89(1):82–88.
   PubMedGoogle Scholar
• Yang BL, Wu WC, Fang KC, et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLOS One. 2015;10(3):e0120443.
   PubMed Web of Science ®Google Scholar
• Koehler EM, Schouten JN, Hansen BE, et al. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11(9):1201–1204.
   PubMed Web of Science ®Google Scholar
• Rogulj D, Konjevoda P, Milic M, et al. Fatty liver index as an indicator of metabolic syndrome. Clin Biochem. 2012;45(1–2):68–71.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–508.
   PubMedGoogle Scholar
• Guiu B, Crevisy-Girod E, Binquet C, et al. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. Eur Radiol. 2012;22(4):855–863.
   PubMed Web of Science ®Google Scholar
• Carretero Gómez J, Arévalo Lorido JC, Gómez Huelgas R, et al. Combination therapy with glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors in older patients with type 2 diabetes: a real-world evidence study. Can J Diabetes. 2019;43(3):186–192.
   PubMed Web of Science ®Google Scholar
• Petit J-M, Bouillet B, Fourmont C, et al. GLP-1 receptor agonist in NAFLD. Diabetes Metab. 2017;43(2):A28–S33.
   Google Scholar
• Akuta N, Kawamura Y, Watanabe C, et al. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res. 2019;49(5):531–539.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–1560.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Stender S, Pietrelli A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018;283(4):356–370.
   PubMed Web of Science ®Google Scholar
• Stefan N, Staiger H, Häring HU. Dissociation between fatty liver and insulin resistance: the role of adipose triacylglycerol lipase. Diabetologia. 2011;54(1):7–9.
   PubMed Web of Science ®Google Scholar
• Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell Metab. 2018;28(4):667–656.
   PubMed Web of Science ®Google Scholar
• Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53(3):413–419.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–1685.
   PubMed Web of Science ®Google Scholar
• Haukeland JW, Konopski Z, Eggesbo HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 2009;44(7):853–860.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690.
   PubMed Web of Science ®Google Scholar
• Petit J-M, Cercueil J-P, Loffroy R, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study. J Clin Endocrinol Metab. 2017;102(2):407–415.
   PubMed Web of Science ®Google Scholar
• Dutour A, Abdesselam I, Ancel P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016;18(9):882–891.
   PubMed Web of Science ®Google Scholar
• Newsome P, Francque S, Harrison S, et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther. 2019;50(2):193–203.
   PubMed Web of Science ®Google Scholar
• Cusi K, Bril F, Barb D, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(4):812–821.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium–glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285–292.
   PubMed Web of Science ®Google Scholar
• Kahl S, Gancheva S, Straßburger K, et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Dia Care. 2020;43(2):298–305.
   PubMed Web of Science ®Google Scholar
• Takase T, Nakamura A, Miyoshi H, et al. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocr J. 2017;64(3):363–367.
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Repetto E, Guja C, et al. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22(3):393–403.
   PubMed Web of Science ®Google Scholar
• Dougherty JA, Guirguis E, Thornby KA. A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. Ann Pharmacother. 2021;55(1):65–79.
   PubMed Web of Science ®Google Scholar